Daewoong Pharmaceutical announced on May 6 that it has completed patient enrollment for the global Phase 2 clinical trial (NCT05389215) of its idiopathic pulmonary fibrosis (IPF) treatment candidate, bersiporocin (DWN12088) (The Asia Business Daily) - May 6, 2026 - "The clinical trial is currently underway in both Korea and the United States, evaluating the safety, tolerability, and efficacy of bersiporocin both as a monotherapy and in combination with existing antifibrotic drugs (nintedanib and pirfenidone)....Based on the results of the global Phase 2 trial, which are expected in the first quarter of 2027, Daewoong Pharmaceutical plans to focus on global partnerships and out-licensing opportunities."
Enrollment closed • P2 data • Idiopathic Pulmonary Fibrosis
|